Both contain semaglutide and improve blood sugar by enhancing insulin release and reducing glucagon. Ozempic is specifically licensed for diabetes at lower doses, while Wegovy provides the same benefits at higher doses alongside more pronounced weight reduction. How semaglutide works on blood sugar Semaglutide, the active ingredient in both Wegovy and Ozempic, belongs to the GLP-1 receptor agonist family. It lowers blood sugar by stimulating insulin release when glucose level

Wegovy is made as a biologic medicine, meaning it uses recombinant technology to produce semaglutide, a protein-based drug. Mysimba and...

The most common side effects with Wegovy are gastrointestinal, such as nausea and diarrhoea, and these often lessen over time. Other medicines have different risks: Orlistat can cause oily stools, Mysimba may raise blood pressure, and phentermine (not used in the UK) carries cardiovascular risks. Understanding risk in context All weight-loss medicines come with benefits and risks. Doctors weigh these carefully before prescribing, taking into account a person’s health conditio

Yes, Wegovy has strong evidence in people with type 2 diabetes, cardiovascular disease, and sleep apnoea, where weight loss can improve outcomes. Other drugs may be chosen if semaglutide is unsuitable, but few have shown the same range of benefits across multiple health conditions. Why certain conditions matter Weight-related health problems often go beyond the number on the scales. People with obesity are more likely to develop type 2 diabetes, cardiovascular disease, and sl

Yes, Wegovy has strong evidence in people with type 2 diabetes, cardiovascular disease, and sleep apnoea, where weight loss can improve...

The most common side effects with Wegovy are gastrointestinal, such as nausea and diarrhoea, and these often lessen over time. Other...

The SELECT trial showed semaglutide 2.4 mg (Wegovy) reduced the risk of major heart problems in people with overweight or obesity and...

No, even though both contain semaglutide, they are licensed for different uses and come in different devices and doses. Doctors may...

The SELECT trial showed semaglutide 2.4 mg (Wegovy) reduced the risk of major heart problems in people with overweight or obesity and cardiovascular disease. Orlistat, while useful for modest weight loss, has not shown the same scale of cardiovascular benefits in large outcome studies. Two very different medicines Wegovy and Orlistat are both prescribed for weight management, but they work in completely different ways. Wegovy (semaglutide) is a GLP-1 receptor agonist that red

No, even though both contain semaglutide, they are licensed for different uses and come in different devices and doses. Doctors may...

In the UK, coverage depends on NHS commissioning rather than insurance, and NICE now recommends Wegovy within specialist services....

In the UK, coverage depends on NHS commissioning rather than insurance, and NICE now recommends Wegovy within specialist services. Saxenda has more limited NHS use. In private healthcare or in other countries, coverage varies by insurer, but newer guidance tends to prioritise Wegovy because of its stronger results. The UK context: NHS commissioning, not insurance Unlike in the United States, where health insurance policies determine which drugs are covered, the UK relies on t

Wegovy works directly on appetite signals in the brain, helping people feel full sooner and think less about food. Other medicines act...

Wegovy works directly on appetite signals in the brain, helping people feel full sooner and think less about food. Other medicines act...

Wegovy has shown sustained weight loss of around 15% at 68 weeks, and many participants maintained benefits at two years. Qsymia (not...

Survey and trial follow-ups suggest people report higher satisfaction with Wegovy than older GLP-1 drugs, mainly because of greater...

Wegovy has shown sustained weight loss of around 15% at 68 weeks, and many participants maintained benefits at two years. Qsymia (not...

Survey and trial follow-ups suggest people report higher satisfaction with Wegovy than older GLP-1 drugs, mainly because of greater...

In a head-to-head trial published in The New England Journal of Medicine , people taking Wegovy lost on average about 15.8% of their body weight over 68 weeks compared with 6.4% for those on Saxenda (liraglutide). This makes Wegovy the more effective of the two for weight loss in most cases. Two GLP-1 medicines, one key difference Both Wegovy and Saxenda belong to the same class of medicines, known as GLP-1 receptor agonists. They work by mimicking a natural hormone that redu

Wegovy contains semaglutide at a higher dose and is licensed for weight management, while Trulicity (dulaglutide) is prescribed for type...